Relatlimab and nivolumab in the treatment of melanoma
- Author(s)
- Au, L; Larkin, J; Turajlic, S;
- Details
- Publication Year 2022-12-22,Volume 185,Issue #26,Page 4866-4869
- Journal Title
- Cell
- Publication Type
- Commentary
- Abstract
- Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.
- Keywords
- Humans; *Nivolumab/therapeutic use; Ipilimumab; *Melanoma/drug therapy/pathology; Antibodies, Monoclonal, Humanized/therapeutic use
- Department(s)
- Laboratory Research; Medical Oncology
- PubMed ID
- 36563660
- Publisher's Version
- https://doi.org/10.1016/j.cell.2022.12.003
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-09-26 05:45:18
Last Modified: 2024-09-26 05:48:04